Welcome
Support Centre
06 September 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose ranging pilot study of ethyl eicosapentaenoate (EPA) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy
ISRCTN ISRCTN44366049
ClinicalTrials.gov identifier
Public title A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose ranging pilot study of ethyl eicosapentaenoate (EPA) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy
Scientific title
Acronym N/A
Serial number at source LA01.01.0002
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Multicentre, double-blind, randomised, parallel group, placebo-controlled, dose ranging pilot study
Countries of recruitment United Kingdom
Disease/condition/study domain Depression
Participants - inclusion criteria 1. Written informed consent
2. Hamilton score of 14 or more
3. Treatment for =8 weeks with one or more standard antidepressants, with no change in antidepressant dosage or drug for at least 4 weeks; likely to be maintained on this treatment and dosage for the duration of the study
4. Diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM IV])
5. Male or female, of any race, aged 18-65
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/2002
Anticipated end date 31/12/2002
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Four groups randomly allocated to placebo or 1 g, 2 g or 4 g ethyl-EPA/day on a double-blind basis. Treatment duration, 12 weeks.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Laxdale Ltd (UK)
Trial website
Publications
Contact name Dr  Harald  Murck
  Address Laxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
  City/town Stirling
  Zip/Postcode FK7 9JQ
  Country United Kingdom
  Tel +44 (0)1786 476001
  Fax +44 (0)1786 473137
  Email hmurck@laxdale.co.uk
Sponsor Laxdale Ltd (UK)
  Address Kings Park House
Laurelhill Business Park
Polmaise Road
  City/town Stirling
  Zip/Postcode FK7 9JQ
  Country United Kingdom
  Tel +44 (0)1786 476001
  Fax +44 (0)1786 473137
  Email admin@Laxdale.co.uk
  Sponsor website: http://www.laxdale.co.uk
Date applied 26/02/2002
Last edited 28/04/2008
Date ISRCTN assigned 26/02/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central